[1] Fischer J,Silva TE,Soares E,et al.From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis.Cytokine,2017,91: 162-169.
[2] Clària J,Arroyo V,Moreau R.The acute-on-chronic liver failure syndrome,or when the innate immune system goes astray. J Immunol,2016,197(10): 3755-3761.
[3] 李雷.细胞因子与肝衰竭的关系及人工肝治疗对其变化的影响.南昌大学学报,2021.
[4] Dong V,Nanchal R,Karvellas CJ.Pathophysiology of acute liver failure.Nutr Clin Pract,2020,35(1): 24-29.
[5] Sarin SK,Choudhury A,Sharma MK,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL):an update.Hepatol Int,2019,13(4): 353-390.
[6] Casulleras M,Zhang IW,López-Vicario C,et al. Systemic inflammation and immunopathology in acute-on-chronic liver failure.Cells,2020,9(12) :2632.
[7] Lin JX,Leonard WJ.Fine-tuning cytokine signals.Annu Rev Immunol,2019,37(12): 295-324.
[8] Triantafyllou E,Woollard KJ,McPhail M,et al.The role of monocytes and macrophages in acute and acute-on-chronic liver failure.Front Immunol,2018,9: 2948.
[9] He Y,Hwang S,Ahmed YA,et al.Immunopathobiology and therapeutic targets related to cytokines in liver diseases.Cell Mol Immunol,2021,18(1): 18-37.
[10] Schmidt-Arras D,Rose-John S.IL-6 pathway in the liver:From physiopathology to therapy.J Hepatol,2016,64(6): 1403-1415.
[11] Li L,Chen L,Lin F,et al.Study of the expression of inflammatory factors IL-4,IL-6,IL-10,and IL-17 in liver failure complicated by coagulation dysfunction and sepsis.J Inflamm Res,2021,14: 1447-1453.
[12] Hunter CA,Jones SA.IL-6 as a keystone cytokine in health and disease.Nat Immunol,2015,16(5): 448-457.
[13] Kaur S,Bansal Y,Kumar R,et al.A panoramic review of IL-6:Structure,pathophysiological roles and inhibitors.Bioorg Med Chem,2020,28(5): 115327.
[14] 陈智,朱海红,杨英.细胞因子风暴与肝衰竭.临床肝胆病杂志,2014,30(10): 981-983.
[15] Widjaja AA,Chothani SP,Cook SA.Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy.Hum Vaccin Immunother,2020,16(10): 2357-2362.
[16] Tsutsui H,Cai X,Hayashi S.Interleukin-1 family cytokines in liver diseases.Mediators Inflamm,2015,2015: 630265.
[17] Chan AH,Schroder K.Inflammasome signaling and regulation of interleukin-1 family cytokines.J Exp Med,2020,217(1).
[18] Barbier L,Ferhat M,Salamé E,et al.Interleukin-1 family cytokines:Keystones in liver inflammatory diseases.Front Immunol,2019,10: 2014.
[19] Gehrke N,Hövelmeyer N,Waisman A,et al.Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation.J Hepatol,2018,68(5): 986-995.
[20] Roth GA,Zimmermann M,Lubsczyk BA,et al.Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure.J Surg Res,2010,163(2): e79-83.
[21] Cayrol C.IL-33,an alarmin of the IL-1 family involved in allergic and non allergic inflammation: Focus on the mechanisms of regulation of its activity.Cells,2021,11(1).
[22] Antunes MM,Araújo AM,Diniz AB,et al.IL-33 signalling in liver immune cells enhances drug-induced liver injury and inflammation.Inflamm Res,2018,67(1): 77-88.
[23] Arshad MI,Patrat-Delon S,Piquet-Pellorce C,et al.Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis.PLoS One,2013,8(9): e74278.
[24] Mantovani A,Dinarello CA,Molgora M,et al.Interleukin-1 and related cytokines in the regulation of inflammation and immunity.Immunity,2019,50(4): 778-795.
[25] Luan J,Ju D.Inflammasome:A double-edged sword in liver diseases.Front Immunol,2018,9: 2201.
[26] Liu Y,Meng X,Wang C,et al.Interleukin-18 plays a positive feedback activity to natural killer-like b cells in hepatitis B virus-associated acute-on-chronic liver failure.Viral Immunol,2022,35(1): 50-59.
[27] Wu Y,Min J,Ge C,et al.Interleukin 22 in liver injury,inflammation and cancer.Int J Biol Sci,2020,16(13): 2405-2413.
[28] Martin-Mateos R,Alvarez-Mon M,Albillos A.Dysfunctional immune response in acute-on-chronic liver failure:It takes two to tango.Front Immunol,2019,10: 973.
[29] Caparrós E,Francés R.The interleukin-20 cytokine family in liver disease.Front Immunol,2018,9: 1155.
[30] Zai W,Chen W,Liu H,Ju D.Therapeutic opportunities of IL-22 in non-alcoholic fatty liver disease: From molecular mechanisms to clinical applications.Biomedicines,2021,9(12).
[31] Kleinschmidt D,Giannou AD,McGee HM,et al.A Protective function of IL-22bp in ischemia reperfusion and acetaminophen-induced liver injury.J Immunol,2017,199(12): 4078-4090.
[32] Ouyang W,O'Garra A.IL-10 Family cytokines IL-10 and IL-22:from basic science to clinical translation.Immunity,2019,50(4): 871-891. |
